HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hemoadsorption in 'Liver Indication'-Analysis of 109 Patients' Data from the CytoSorb International Registry.

AbstractBACKGROUND:
Our aim is to report the results of the 'liver indication' subset of patients in the CytoSorb International Registry.
METHODS:
Structured data were recorded. Treatment characteristics and changes from T1 (start of hemoadsorption) to T2 (termination) were evaluated with a special focus on bilirubin, C-reactive protein, procalcitonin, interleukin-6, platelet levels, SOFA scores, mortality, and subjective assessment by the attending physicians.
RESULTS:
Until January 2021, from the total 1434 patients, 109 (age: 49.2 ± 17.1 years, 57.8% males) received treatment for hyperbilirubinemia. APACHE II-predicted mortality was 49.6 ± 26.8%. In the study, 91% of patients were alive at the termination of hemoadsorption and improvement was observed by the physicians in 75 cases. Overall, 65 (59.6%) patients died in the hospital, and 60 (55.0%) died in the ICU. Patients received a median of two treatments for a median of 43 h (interquartile range: 24-72 h) in total. Serum bilirubin levels reduced significantly to -4.6 (95% CI: -6.329 to -2.8) mg/dL. Thrombocytopenia was reported in four patients as an adverse event.
CONCLUSIONS:
We report the largest case series on hemoadsorption for 'liver indication' from the CytoSorb International Registry. The finding of significant bilirubin removal observed in our study could have substantial impact in designing and executing further studies on the effects of hemoadsorption in liver dysfunction, which are certainly warranted.
AuthorsKlementina Ocskay, Dana Tomescu, Andreas Faltlhauser, David Jacob, Sigrun Friesecke, Manu Malbrain, Klaus Kogelmann, Ralph Bogdanski, Friedhelm Bach, Harald Fritz, Andreas Hartjes, Andreas Kortgen, Jens Soukup, Stefan Utzolino, Martijn van Tellingen, Karl Träger, Ulrike Schumacher, Frank M Brunkhorst, Zsolt Molnar
JournalJournal of clinical medicine (J Clin Med) Vol. 10 Issue 21 (Nov 05 2021) ISSN: 2077-0383 [Print] Switzerland
PMID34768702 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: